Literature DB >> 25483631

Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India.

Shantanu K Kar1, Alfred Pach, Binod Sah, Anna S Kerketta, Bikash Patnaik, VijayaLaxmi Mogasale, Yang Hee Kim, Shyam Bandhu Rath, Sunheang Shin, Hemant K Khuntia, Anuj Bhattachan, Mahesh K Puri, Thomas F Wierzba, Linda M Kaljee.   

Abstract

Approximately 30% of reported global cholera cases occur in India. In 2011, a household survey was conducted 4 months after an oral cholera vaccine pilot demonstration project in Odisha India to assess factors associated with vaccine up-take and exposure to a communication and social mobilization campaign. Nine villages were purposefully selected based on socio-demographics and demonstration participation rates. Households were stratified by level of participation and randomly selected. Bivariate and ordered logistic regression analyses were conducted. 517/600 (86%) selected households were surveyed. At the household level, participant compared to non-participant households were more likely to use the local primary health centers for general healthcare (P < 0.001). Similarly, at the village level, higher participation was associated with use of the primary health centers (P < 0.001) and private clinics (p = 0.032). Also at the village level, lower participation was associated with greater perceived availability of effective treatment for cholera (p = 0.013) and higher participation was associated with respondents reporting spouse as the sole decision-maker for household participation in the study. In terms of pre-vaccination communication, at the household level verbal communication was reported to be more useful than written communication. However written communication was perceived to be more useful by respondents in low-participating villages compared to average-participating villages (p = 0.007) These data on participation in an oral cholera vaccine demonstration program are important in light of the World Health Organization's (WHO) recommendations for pre-emptive use of cholera vaccine among vulnerable populations in endemic settings. Continued research is needed to further delineate barriers to vaccine up-take within and across targeted communities in low- and middle-income countries.

Entities:  

Keywords:  Bhubaneswar India; WHO; DHS; Directorate of Health Services; India; International Vaccine Institute; PHC; Odisha India; ORC; Oral Cholera Vaccine; IVI; Primary Health Centers; RMRC; Regional Medical Research Center; World Health Organization; cholera; communication campaigns; social-behavioral research; vaccine up-take

Mesh:

Substances:

Year:  2014        PMID: 25483631      PMCID: PMC5443101          DOI: 10.4161/21645515.2014.971655

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  21 in total

Review 1.  Cholera vaccine: new preventive tool for endemic countries.

Authors:  Ramesh Verma; Pardeep Khanna; Suraj Chawla
Journal:  Hum Vaccin Immunother       Date:  2012-05-01       Impact factor: 3.452

2.  Cholera vaccines: WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2010-03-26

3.  Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam.

Authors:  Linda M Kaljee; Van Pham; Nguyen Dinh Son; Nguyen Thai Hoa; Vu Dinh Thiem; Do Gia Canh; Le Thi Kim Thoa; Mohammad Ali; Rion Leon Ochiai; M Carolina Danovaro-Holliday; Camilo J Acosta; Bonita Stanton; John Clemens
Journal:  Trop Med Int Health       Date:  2007-01       Impact factor: 2.622

4.  Typhoid vaccines: WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-02-08

Review 5.  Vaccinations in the Third World: a consideration of community demand.

Authors:  M Nichter
Journal:  Soc Sci Med       Date:  1995-09       Impact factor: 4.634

Review 6.  Vaccines in the time of cholera.

Authors:  John D Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-11       Impact factor: 11.205

Review 7.  Sociobehavioural research methods for the introduction of vaccines in the Diseases of the Most Impoverished Programme.

Authors:  Linda M Kaljee; Rob Pack; Al Pach; Andrew Nyamete; Bonita F Stanton
Journal:  J Health Popul Nutr       Date:  2004-09       Impact factor: 2.000

8.  Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.

Authors:  Dipika Sur; Anna Lena Lopez; Suman Kanungo; Allison Paisley; Byomkesh Manna; Mohammad Ali; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Allan Donner; Nirmal K Ganguly; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens
Journal:  Lancet       Date:  2009-10-08       Impact factor: 79.321

9.  The case for reactive mass oral cholera vaccinations.

Authors:  Rita Reyburn; Jacqueline L Deen; Rebecca F Grais; Sujit K Bhattacharya; Dipika Sur; Anna L Lopez; Mohamed S Jiddawi; John D Clemens; Lorenz von Seidlein
Journal:  PLoS Negl Trop Dis       Date:  2011-01-25

10.  Controlling endemic cholera with oral vaccines.

Authors:  Ira M Longini; Azhar Nizam; Mohammad Ali; Mohammad Yunus; Neeta Shenvi; John D Clemens
Journal:  PLoS Med       Date:  2007-11-27       Impact factor: 11.069

View more
  4 in total

1.  "You need to be an advocate for yourself": Factors associated with decision-making regarding influenza and pneumococcal vaccine use among US older adults from within a large metropolitan health system.

Authors:  Linda M Kaljee; Paul Kilgore; Tyler Prentiss; Lois Lamerato; Daniela Moreno; Samia Arshad; Marcus Zervos
Journal:  Hum Vaccin Immunother       Date:  2016-09-13       Impact factor: 3.452

2.  An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India.

Authors:  Vittal Mogasale; Shantanu K Kar; Jong-Hoon Kim; Vijayalaxmi V Mogasale; Anna S Kerketta; Bikash Patnaik; Shyam Bandhu Rath; Mahesh K Puri; Young Ae You; Hemant K Khuntia; Brian Maskery; Thomas F Wierzba; Binod Sah
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

Review 3.  The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.

Authors:  Lina Odevall; Deborah Hong; Laura Digilio; Sushant Sahastrabuddhe; Vittal Mogasale; Yeongok Baik; Seukkeun Choi; Jerome H Kim; Julia Lynch
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

4.  Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia.

Authors:  Samuel Teshome; Sachin Desai; Jerome H Kim; Dires Belay; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2018-05-10       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.